Literature DB >> 28954288

Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?

Boris Freidlin1, Edward L Korn1.   

Abstract

Factorial 2 × 2 designs can be used to combine evaluation of two treatments in a single study. The standard analysis approach is based on a factorial analysis that evaluates each treatment by pooling data over the other treatment. This approach relies on the assumption that the effect of each treatment is not substantially affected by the other treatment. In many oncology settings, this no-interaction assumption cannot be adequately supported at the time the trial is designed. In this Commentary, we consider current practices for the design and analysis of factorial trials by performing a survey of factorial treatment trials published in the Journal of the National Cancer Institute, Journal of Clinical Oncology, and the New England Journal of Medicine (2007-2016). The protocol-specified sample size was derived based on the factorial (pooled) analysis in 96.7% of the 30 identified trials, and the factorial analysis was specified as the primary analysis in 90.0% of these identified trials. An interaction complicating study interpretation was reported in 16.7% of the trials. We provide recommendations for matching the trial analysis and design to the study goals to account for possible interaction and illustrate the recommendations on the data from several published trials. Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Mesh:

Year:  2017        PMID: 28954288      PMCID: PMC6059117          DOI: 10.1093/jnci/djx146

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  16 in total

Review 1.  Multi-arm clinical trials of new agents: some design considerations.

Authors:  Boris Freidlin; Edward L Korn; Robert Gray; Alison Martin
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

2.  Bayesian design and analysis of two x two factorial clinical trials.

Authors:  R Simon; L S Freedman
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

3.  Factorial designs in clinical trials: the effects of non-compliance and subadditivity.

Authors:  E Brittain; J Wittes
Journal:  Stat Med       Date:  1989-02       Impact factor: 2.373

4.  Factorial designs for randomized clinical trials.

Authors:  D P Byar; S Piantadosi
Journal:  Cancer Treat Rep       Date:  1985-10

5.  Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Authors:  Eric A Klein; Ian M Thompson; Catherine M Tangen; John J Crowley; M Scott Lucia; Phyllis J Goodman; Lori M Minasian; Leslie G Ford; Howard L Parnes; J Michael Gaziano; Daniel D Karp; Michael M Lieber; Philip J Walther; Laurence Klotz; J Kellogg Parsons; Joseph L Chin; Amy K Darke; Scott M Lippman; Gary E Goodman; Frank L Meyskens; Laurence H Baker
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

Review 6.  Analysis and reporting of factorial trials: a systematic review.

Authors:  Finlay A McAlister; Sharon E Straus; David L Sackett; Douglas G Altman
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

7.  Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.

Authors:  Eric C Larsen; Meenakshi Devidas; Si Chen; Wanda L Salzer; Elizabeth A Raetz; Mignon L Loh; Leonard A Mattano; Catherine Cole; Alisa Eicher; Maureen Haugan; Mark Sorenson; Nyla A Heerema; Andrew A Carroll; Julie M Gastier-Foster; Michael J Borowitz; Brent L Wood; Cheryl L Willman; Naomi J Winick; Stephen P Hunger; William L Carroll
Journal:  J Clin Oncol       Date:  2016-04-25       Impact factor: 44.544

8.  Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Authors:  Joseph A Sparano; Fengmin Zhao; Silvana Martino; Jennifer A Ligibel; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2015-06-15       Impact factor: 44.544

Review 9.  Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

Authors:  James M S Wason; Lynne Stecher; Adrian P Mander
Journal:  Trials       Date:  2014-09-17       Impact factor: 2.279

10.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.

Authors:  Matthew R Sydes; Mahesh K B Parmar; Nicholas D James; Noel W Clarke; David P Dearnaley; Malcolm D Mason; Rachel C Morgan; Karen Sanders; Patrick Royston
Journal:  Trials       Date:  2009-06-11       Impact factor: 2.279

View more
  7 in total

1.  The Surveillance After Extremity Tumor Surgery (SAFETY) trial: protocol for a pilot study to determine the feasibility of a multi-centre randomised controlled trial.

Authors: 
Journal:  BMJ Open       Date:  2019-09-18       Impact factor: 2.692

2.  Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently.

Authors:  Ian R White; Babak Choodari-Oskooei; Matthew R Sydes; Brennan C Kahan; Leanne McCabe; Anna Turkova; Hanif Esmail; Diana M Gibb; Deborah Ford
Journal:  Clin Trials       Date:  2022-05-17       Impact factor: 2.599

3.  A multicentric, 2 × 2 factorial, randomised, open-label trial to evaluate the clinical effectiveness of structured physical activity training and cognitive behavioural therapy versus usual care in heart failure patients: a protocol for the PACT-HF trial.

Authors:  Panniyammakal Jeemon; Salim Reethu; Sanjay Ganapathi; Lakshmipuram Rajappan Lakshmi Kanth; Eapen Punnoose; Jabir Abdullakutty; Shafeeq Mattumal; Johny Joseph; Stigi Joseph; Chitra Venkateswaran; Poornima Sunder; Abraham Samuel Babu; Sebastian Padickaparambil; Kandagathuparambil Rajan Neenumol; Susanna Chacko; Shamla Shajahan; Krishnaja Krishnankutty; Selma Devis; Rani Joseph; Bhagavathikandy Shemija; Sneha Anna John; Sivadasanpillai Harikrishnan
Journal:  Wellcome Open Res       Date:  2022-08-12

Review 4.  Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.

Authors:  Aaron C Tan; Stephen J Bagley; Patrick Y Wen; Michael Lim; Michael Platten; Howard Colman; David M Ashley; Wolfgang Wick; Susan M Chang; Evanthia Galanis; Alireza Mansouri; Simon Khagi; Minesh P Mehta; Amy B Heimberger; Vinay K Puduvalli; David A Reardon; Solmaz Sahebjam; John Simes; Scott J Antonia; Don Berry; Mustafa Khasraw
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

5.  Acupuncture and clomiphene for Chinese women with polycystic ovary syndrome (PCOSAct): statistical analysis approach with the revision and explanation.

Authors:  Hong-Li Ma; Liang-Zhen Xie; Jing-Shu Gao; Jing Cong; Ying-Ying Deng; Ernest H Y Ng; Jian-Ping Liu; Xiao-Ke Wu
Journal:  Trials       Date:  2018-11-01       Impact factor: 2.279

6.  The effect of co supplementation of omega-3 and vitamin D on cardio metabolic risk factors and psychological distress in reproductive-aged women with prediabetes and hypovitaminosis D: a study protocol for a randomized controlled trial.

Authors:  Masoumeh Rajabi-Naeeni; Mahrokh Dolatian; Mostafa Qorbani; Amir Abbas Vaezi
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

7.  Effect of omega-3 and vitamin D co-supplementation on psychological distress in reproductive-aged women with pre-diabetes and hypovitaminosis D: A randomized controlled trial.

Authors:  Masoumeh Rajabi-Naeeni; Mahrokh Dolatian; Mostafa Qorbani; Amir Abbas Vaezi
Journal:  Brain Behav       Date:  2021-09-02       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.